Mauskopf J, Earnshaw S. Budget-impact analyses. In: Rascati, K, editors. Essentials of pharmacoeconomics: health economics and outcomes research. 3rd ed. Alphen aan den Rijn: The Netherlands. Wolters Kluwer; 2020.
Purser M, Hartley L, Earnshaw S, Bhaila R, Nag A. Economic models used to evaluate the cost-effectiveness of biologic treatments for ulcerative colitis: a systematic literature review. Poster presented at the 2020 Virtual UEG Week Conference; October 11, 2020.
Purser M, Hartley L, Earnshaw S, Bhaila R, Nag A. Systematic literature review to assess the healthcare resource use and costs associated with ulcerative colitis in adults in Europe. Poster presented at the 2020 Virtual UEG Week Conference; October 11, 2020.
Earnshaw SR, Beyhaghi H, McDade C, Ferris Purser M, Marriott R, Daane L, Le Coent V, Yang J, Toback S. Economic evaluation of large volume delayed sampling and pathogen reduction technology strategies for processing platelets. Poster presented at the 2020 Virtual AABB Annual Meeting; October 2020.
Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6
Mullins CD, Earnshaw SR, Brodtkorb T-H. Budget impact analysis I - A 6-step approach. Presented at the 2020 ISPOR Virtual Conference; June 18, 2020.
Beyhaghi H, Zimmer L, McDade C, Purser M, Blanc E, Pavlov V, Earnshaw S. The cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury. Poster presented at the 2020 Digital 33rd European Society of Intensive Care Medicine (ESICM) Congress; December 6, 2020. [abstract] Intensive Care Med Exp. 2020; 8(Suppl 2):000107.
Earnshaw SR, Taylor TN, McDade CL. Pharmacoeconomics and the drug development process.. In: Yih Y, editors. Handbook of healthcare delivery systems. Boca Raton: FL. CRC Press; 2010.
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the 9th Canadian Immunization Conference; December 2010. Previously presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Mladsi DM, Redekop K, Goettsch A, Earnshaw SR. Challenges and insights in establishing and communicating the economic value of companion diagnostics. Presented at the 2010 ISPOR 13th Annual European Congress; November 2010. Prague, Czech Republic.
Mladsi D, Earnshaw S, Ronquest NA, Keith M. The threshold pricing model: not just another cost-effectiveness model. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A332.
Mladsi D, Earnshaw S, Akashi-Ronquest N, Keith M. Proposed methods for conducting sensitivity analyses on threshold-derived estimates of value-based price and product profiles of early stage drugs. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A333.
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.
Jackson D, Earnshaw SR, Farkouh R, Schwamm L. Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective. Am J Neuroradiol. 2010 Oct 1;31(9):1669-74.
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2010.
Rinaldi F, Hwang S, Strutton D, Earnshaw S, Farkouh R. Clinical and economic impact of 13-valent pneumococcal conjugate vaccination in Singapore and Hong Kong. Poster presented at the 2010 ISPOR 15th Annual International Meeting; June 2, 2010.
Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.
Earnshaw S, Pignone M, Fendrick AM, Scheiman J, McDade C. Cost-effectiveness of proton pump inhibitors for prevention of gastrointestinal adverse events when using aspirin for primary cardiovascular prevention. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A166.
Jackson D, Earnshaw S, Farkouh RA, Schwamm LH. Cost-effectiveness of perfusion imaging with computed tomography to identify patients for intravenous thrombolysis: a hospital perspective. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A175.
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Graham JB, Earnshaw SR, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A381.
Earnshaw SR. Pharmacoeconomics and decision analysis. Presented at the North Carolina State University; November 2007.
Zyczynski TM, Beard SM, Earnshaw SR, McDade CL. Cost-effectiveness analysis of the use of iodixanol compared to iohexol in the United Kingdom. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007.
Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007 Oct 1;23(10):2517-29.
Earnshaw SR, Wilson MR, Blanchette C. Cost-effectiveness of salmeterol/fluticasone propionate in the treatment of COPD: estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the Annual Meeting of the American College of Chest Physicians; October 2007.
Earnshaw SR, McDade CL, Mangel AW, Baran RW. Cost-effectiveness of lubiprostone in a managed care population with chronic idiopathic constipation. Poster presented at the 2007 ACG Annual Meeting; September 2007. [abstract] Am J Gastroenterol. 2007 Sep; 102(S2):S449-50.
Earnshaw SR, Graham CN, Gasper S. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis. Poster presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 2007.
Earnshaw SR, Hicks K, Richter A, Honeycutt A. A linear programming model for allocating HIV prevention funds with state agencies: a pilot study. Health Care Manag Sci. 2007 Sep 1;10(3):239-52.
Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007 Sep 1;29(9):2096-106.
Lynch NO, Earnshaw SR, Graham CN, Patroe V, Boisdron J, Middelhoven H. Ibandronate IV injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Poster presented at the European League Against Rheumatism (EULAR) 2007 Annual European Congress of Rheumatology; June 2007.
Earnshaw SR, Okazawa M, Wilson MR, Blanchette C. Estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the International Conference of the American Thoracic Society; May 2007.
Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.
Graham CN, Earnshaw SR, Saunders M. Assessing the impact of smoking cessation therapies on a managed care organization's budget using census region and state-specific smoking estimates. Poster presented at the Academy of Managed Care Pharmacy 19th Annual Meeting Showcase; April 14, 2007.
Earnshaw SR, Sikirica V, Roskell NS, Shannon PR, Beard S, Schein J, Doshi D, Janagap C. Economic analysis of short-course levofloxacin versus amoxicillin/clavulanate in treating acute bacterial exacerbations of chronic bronchitis. Poster presented at the Academy of Managed Care Pharmacy 19th Annual Meeting Showcase; April 14, 2007.
Earnshaw SR, Brogan AJ. Markov-model toolkit: concepts and assumptions. Presented at the 19th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy; April 2007. San Diego, CA.
Bell C, Graham JB, Earnshaw S, Oleen-Burkey MK, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007 Apr 1;13(3):245-61.
Lynch NO, Earnshaw SR, Graham CN, Middelhoven H. Cost-effectiveness of ibandronate injection IV in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates. Poster presented at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO); March 2007.
Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007 Feb 12;167(3):290-5.
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.